PharmAust, Genzyme form alliance to provide peptide products, services to customers

By E. Janene Geiss

Philadelphia, Jan. 27 - PharmAust Ltd. said Friday that its wholly owned subsidiary, Mimotopes Pty Ltd., has signed an exclusive and global strategic alliance agreement with Genzyme Corp. to provide a total suite of peptide products and services to both companies' customer bases.

The agreement, effective Feb. 1, allows Mimotopes to join forces with Genzyme's business unit, Genzyme Pharmaceuticals, to develop and manufacture peptide and lipid products and technologies to provide products and services for research use to therapeutic grade peptides, officials said.

The alliance offers customers an integrated "one-stop-shop," officials said, from laboratory to clinic by way of an exclusive referral agreement.

Mimotopes said it will supply customers with research grade peptides and related services up to the point of lead candidate identification in preclinical applications.

Genzyme said it will supply customers with identified lead candidate peptides for preclinical applications through to clinical and therapeutic grade peptides and related services.

Melbourne, Australia-based Mimotopes develops preclinical peptides for biological and pharmaceutical applications.

Genzyme, based in Cambridge, Mass., develops and manufactures specialty pharmaceutical delivery materials and value-added technologies, products and services with a focus on peptide, amino acid derivative, lipid and drug-delivery markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.